The IMpower133 trial, comparing carboplatin plus etoposide with or without atezolizumab, a PD-L1 inhibitor, in the first-line treatment of patients with ES-SCLC, showed only a two-month improvement in OS in the atezolizumab arm. The gene discussed is CD274; the disease is small cell lung carcinoma.